tiprankstipranks

Mark Sieczkarek Insider Profile

4 Followers
Mark Sieczkarek, Director at NovaBay Pharma, holds 1.16M shares in NovaBay Pharma (Ticker: NBY), holds ― shares in Mawson Infrastructure Group (Ticker: MIGI), holds 0.00 shares in Solta Medical Inc (Ticker: SLTM).
tipranks
Mark Sieczkarek

Mark Sieczkarek
NovaBay Pharma (NBY)
Director

Ranked #78,738 out of 98,743 Corporate Insiders

Profitable Transactions

25%
1 out of 4 Profitable Transactions

Average Return

-23.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$103K
100.00%
0.00%
A breakdown of Mark Sieczkarek's holdings

Insider Roles

NovaBay Pharma
(NBY)
Director
Mawson Infrastructure Group
(MIGI)
Director
Roles that Mark Sieczkarek holds in companies

Most Profitable Insider Trade

Stock:
NovaBay Pharma
(NBY)
Rating:Informative Buy
Date:Oct 03, 2016 - Oct 03, 2017
Return:+12.70%
The most profitable trade made by Mark Sieczkarek

Mark Sieczkarek's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
NovaBay Pharma
Aug 06, 2019
Director
Uninformative Buy
$102.96K
Mawson Infrastructure Group
Director
SLTM
Solta Medical Inc
Jan 27, 2014
Uninformative Sell
786.98K
List of latest transactions for each holding click on a transaction to see Mark Sieczkarek's performance on stock

Mark Sieczkarek insider profile FAQ

What is the percentage of profitable transactions made by Mark Sieczkarek?
The percentage of profitable transactions made by Mark Sieczkarek is 25%.
    What is the average return per transaction made by Mark Sieczkarek?
    The average return per transaction made by Mark Sieczkarek is -23.60%.
      What stocks does Mark Sieczkarek hold?
      Mark Sieczkarek holds: NBY, MIGI, SLTM stocks.
        What was Mark Sieczkarek’s latest transaction?
        Mark Sieczkarek latest transaction was an Uninformative Buy of ―.
          What was Mark Sieczkarek's most profitable transaction?
          Mark Sieczkarek’s most profitable transaction was an Informative Buy of NBY stock on October 3, 2016. The return on the trade was 12.70%.
            What is Mark Sieczkarek's role in NovaBay Pharma?
            Mark Sieczkarek's role in NovaBay Pharma is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.